Skip to main content
SpringerLink
Log in

Male Hypogonadism

  • Chapter
  • First Online:
Endocrinology and Diabetes

Abstract

The testes are vital organs for reproduction of the human species, besides being the main source of testosterone production in men. Thus, although not essential for survival, they represent the essence of male biological function.

The clinical features of male hypogonadism are sufficiently well recognized, the causes sufficiently well known, and the tests of the hypothalamic–pituitary–testicular axis sufficiently accurate to permit the diagnosis in most patients.

Hypogonadism in a male refers to a decrease in one or both of the two major functions of the testes: sperm production or testosterone production. These abnormalities can result from disease of the testes (primary hypogonadism) or disease of the pituitary or hypothalamus (secondary hypogonadism).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Krausz C. Male infertility: pathogenesis and clinical diagnosis. Best Pract Res Clin Endocrinol Metab. 2011;25(2):271–85.

    Article  PubMed  Google Scholar 

  2. Grinspon RP, Loreti N, Braslavsky D, Bedecarrás P, Ambao V, et al. Sertoli cell markers in the diagnosis of paediatric male hypogonadism. J Pediatr Endocrinol Metab. 2012;25(1–2):3–11.

    CAS  PubMed  Google Scholar 

  3. Grinspon RP, Rey RA. New perspectives in the diagnosis of pediatric male hypogonadism: the importance of AMH as a Sertoli cell marker. Arq Bras Endocrinol Metabol. 2011;55(8):512–9.

    Article  PubMed  Google Scholar 

  4. Tsutsumi R, Webster NJ. GnRH pulsatility, the pituitary response and reproductive dysfunction. Endocr J. 2009;56(6):729–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ohlsson C, Wallaschofski H, Lunetta KL, Stolk L, Perry JRB, et al. Genetic determinants of serum testosterone concentrations in men. PLoS Genet. 2011;7(10):1–11.

    Article  Google Scholar 

  6. Salenave S, Trabado S, Maione L, Brailly-Tabard S, Young J. Male acquired hypogonadotropic hypogonadism: diagnosis and treatment. Ann Endocrinol (Paris). 2012;73(2):141–6.

    Article  Google Scholar 

  7. Groth KA, Skakkebaek A, Host C, Gravholt CH, Bojesen A. Klinefelter syndrome-a clinical update. J Clin Endocrinol Metab. 2012;98(1):20–30.

    Article  PubMed  Google Scholar 

  8. Ottesen AM, Aksglaede L, Garn I, Tartaglia N, Tassone F, Gravholt CH, et al. Increased number of sex chromosomes affects height in a nonlinear fashion: a study of 305 patients with sex chromosome aneuploidy. Am J Med Genet A. 2010;152A(5):1206–12.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Herlihy AS, Halliday JL, Cock ML, RI M. The prevalence and diagnosis rates of Klinefelter syndrome: an Australian comparison. Med J Aust. 2011;194(1):24–8.

    Article  PubMed  Google Scholar 

  10. Morris JKAE, Scott C, Jacobs P. Is the prevalence of Klinefelter syndrome increasing? Eur J Hum Genet. 2008;16(2):163–70.

    Article  CAS  PubMed  Google Scholar 

  11. Swerdlow AJ, Higgins CD, Schoemaker MJ, Wright AF, Jacobs PA. Mortality in patients with Klinefelter syndrome in Britain: a cohort study. J Clin Endocrinol Metab. 2005;90(12):6516–22.

    Article  CAS  PubMed  Google Scholar 

  12. Bojesen A, Juul S, Birkebaek NH, Gravholt CH. Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses. J Clin Endocrinol Metab. 2006;91(4):1254–60.

    Article  CAS  PubMed  Google Scholar 

  13. Oates RD. The natural history of endocrine function and spermatogenesis in Klinefelter syndrome: what the data show. Fertil Steril. 2012;98(2):266–73.

    Article  CAS  PubMed  Google Scholar 

  14. Savic I. Advances in research on the neurological and neuropsychiatric phenotype of Klinefelter syndrome. Curr Opin Neurol. 2012;25(2):138–43.

    PubMed  Google Scholar 

  15. Mendeluk GR, Pardes EM, López-Costa S. 45,X/46,XY qh- karyotype and aspermia. A case report. Tsitol Genet 2012;46(4):27–30.

    Google Scholar 

  16. Lindhardt Johansen M, Hagen CP, Rajpert-De Meyts E, Kjærgaard S, Petersen BL. 45, X/46, XY mosaicism: phenotypic characteristics, growth, and reproductive function–a retrospective longitudinal study. J Clin Endocrinol Metab. 2012;97(8):1540–9.

    Article  Google Scholar 

  17. Templado C, Vidal F, Estop A. Aneuploidy in human spermatozoa. Cytogenet Genome Res. 2011;133(2–4):91–9.

    Article  CAS  PubMed  Google Scholar 

  18. Cruz Guzmán Odel R, Chávez García AL, Rodríguez-Cruz M. Muscular dystrophies at different ages: metabolic and endocrine alterations. Int J Endocrinol. 2012;2012:1–12.

    Article  Google Scholar 

  19. Al-Harbi TM, Bainbridge LJ, McQueen MJ, Tarnopolsky MA. Hypogonadism is common in men with myopathies. J Clin Neuromuscul Dis. 2008;9(4):397–401.

    Article  PubMed  Google Scholar 

  20. Belchetz PE, Barth JH, Kaufman JM. Biochemical endocrinology of the hypogonadal male. Ann Clin Biochem. 2010;47(6):503–15.

    Article  CAS  PubMed  Google Scholar 

  21. Menon KM, Menon B. Structure, function and regulation of gonadotropin receptors—a perspective. Mol Cell Endocrinol. 2012;356(1–2):88–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Brioude F, Bouvattier CE, Lombès M. Hypogonadotropic hypogonadism: new aspects in the regulation of hypothalamic-pituitary-gonadal axis. Ann Endocrinol (Paris). 2010;71 suppl 1:s33–41.

    Article  CAS  Google Scholar 

  23. Pitteloud N, Durrani S, Raivio T, Sykiotis GP. Complex genetics in idiopathic hypogonadotropic hypogonadism. Front Horm Res. 2010;39:142–53.

    Article  CAS  PubMed  Google Scholar 

  24. Robin G, Boitrelle F, Marcelli F, Colin P, Leroy-Martin B, et al. Cryptorchidism: from physiopathology to infertility. Gynecol Obstet Fertil. 2010;38(10):588–99.

    Article  CAS  PubMed  Google Scholar 

  25. Hutson JM, Balic A, Nation T, Southwell B. Cryptorchidism. Semin Pediatr Surg. 2010;10(3):215–24.

    Article  Google Scholar 

  26. Brauner R, Neve M, Allali S, Trivin C, Lottmann H, et al. Clinical, biological and genetic analysis of anorchia in 26 boys. PLoS One. 2011;6(8):23292.

    Article  Google Scholar 

  27. Shiraishi K, Matsuyama H, Takihara H. Pathophysiology of varicocele in male infertility in the era of assisted reproductive technology. Int J Urol. 2012;19(6):538–50.

    Article  CAS  PubMed  Google Scholar 

  28. Iglesias P, Carrero JJ, Díez JJ. Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J Nephrol. 2012;25(1):31–42.

    Article  CAS  PubMed  Google Scholar 

  29. Foresta C, Schipilliti M, Ciarleglio FA, Lenzi A, D’Amico D. Male hypogonadism in cirrhosis and after liver transplantation. J Endocrinol Investig. 2008;31(5):470–8.

    Article  CAS  Google Scholar 

  30. Young J. Endocrine consequences of hemochromatosis. Presse Med. 2007;36(9):1319–25.

    Article  PubMed  Google Scholar 

  31. Rochira V, Zirilli L, Orlando G, Santi D, Brigante G, et al. Premature decline of serum total testosterone in HIV-infected men in the HAART-Era. PLoS One. 2011;6(12):e28512.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol. 2005;6(4):209–18.

    Article  PubMed  Google Scholar 

  33. Dohle GR. Male infertility in cancer patients: review of the literature. Int J Urol. 2010;17(4):327–31.

    Article  PubMed  Google Scholar 

  34. Davis JE, Silverman M. Scrotal emergencies. Emerg Med Clin North Am. 2011;29(3):469–84.

    Article  PubMed  Google Scholar 

  35. Dajusta DG, Granberg CF, Villanueva C, Baker LA. Contemporary review of testicular torsion: new concepts, emerging technologies and potential therapeutics. J Pediatr Urol. 2012;S1477–5131(12):00221–5.

    Google Scholar 

  36. Woodruff DY, Horwitz G, Weigel J, Nangia AK. Fertility preservation following torsion and severe ischemic injury of a solitary testes. Fertil Steril. 2010;94(1):352.

    Article  PubMed  Google Scholar 

  37. Ankley GT, Cavallin JE, Durhan EJ, Jensen KM, Kahl MD, et al. A time-course analysis of effects of the steroidogenesis inhibitor ketoconazole on components of the hypothalamic-pituitary-gonadal axis of fathead minnows. Aquat Toxicol. 2012;114–115:88–95.

    Article  PubMed  Google Scholar 

  38. Salehian B, Kejriwal K. Glucocorticoid-induced muscle atrophy: mechanisms and therapeutic strategies. Endocr Pract. 1999;5(5):277–81.

    Article  CAS  PubMed  Google Scholar 

  39. Hu GX, Lian QQ, Lin H, Latif SA, Morris DJ, et al. Rapid mechanisms of glucocorticoid signaling in the Leydig cell. Steroids. 2008;73(9–10):1018–24.

    Article  CAS  PubMed  Google Scholar 

  40. Viswanathan V, Eugster EA. Etiology and treatment of hypogonadism in adolescents. Pediatr Clin N Am. 2011;58(5):1181–200.

    Article  Google Scholar 

  41. Young J. Approach to the male patient with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2012;97(3):707–18.

    Article  CAS  PubMed  Google Scholar 

  42. Bonomi M, Libri DV, Guizzardi F, Guarducci E, Maiolo E, et al. New understandings of the genetic basis of isolated idiopathic central hypogonadism. Asian J Androl. 2012;14(1):49–56.

    Article  CAS  PubMed  Google Scholar 

  43. Hardelin JP, Dodé C. The complex genetics of Kallmann syndrome: KAL1, FGFR1, FGF8, PROKR2, PROK2, et al. Sex Dev. 2008;2(4–5):181–93.

    Article  CAS  PubMed  Google Scholar 

  44. Semple RK, Topaloglu AK. The recent genetics of hypogonadotrophic hypogonadism — novel insights and new questions. Clin Endocrinol. 2010;72(4):427–35.

    Article  CAS  Google Scholar 

  45. Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, et al. Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med. 2007;357(9):863–73.

    Article  CAS  PubMed  Google Scholar 

  46. Bahceci M, Dolek D, Tutuncuoglu P, Gorgel A, Oruk G, et al. A case series of Bardet-Biedl syndrome in a large Turkish family and review of the literature. Eat Weight Disord. 2012;17(1):e66–9.

    Article  CAS  PubMed  Google Scholar 

  47. Iannello S, Bosco P, Cavaleri A, Camuto M, Milazzo P, et al. A review of the literature of Bardet-Biedl disease and report of three cases associated with metabolic syndrome and diagnosed after the age of fifty. Obes Rev. 2002;3(2):123–35.

    Article  CAS  PubMed  Google Scholar 

  48. Bolyakov A, Paduch DA. Prolactin in men’s health and disease. Curr Opin Urol. 2011;21(6):527–34.

    Article  PubMed  Google Scholar 

  49. Kanayama G, Pope HG Jr. Illicit use of androgens and other hormones: recent advances. Curr Opin Endocrinol Diabetes Obes. 2012;19(3):211–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Smith HS, Elliott JA. Opioid-induced androgen deficiency (OPIAD). Pain Physician. 2012;15(3 Suppl):145–56.

    Google Scholar 

  51. Elliott JA, Opper SE, Agarwal S, Fibuch EE. Non-analgesic effects of opioids: opioids and the endocrine system. Curr Pharm Des. 2012;18(37):6070–8.

    Article  CAS  PubMed  Google Scholar 

  52. De Maddalena C, Bellini M, Berra M, Meriggiola MC, Aloisi AM. Opioid-induced hypogonadism: why and how to treat it. Pain Physician. 2012;15:ES111–8.

    PubMed  Google Scholar 

  53. Chauhan S, Diamond MP. Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men. Fertil Steril. 2005;84(1):186–90.

    Article  CAS  PubMed  Google Scholar 

  54. Jóźków P, Mędraś M. Psychological stress and the function of male gonads. Endokrynol Pol. 2012;63(1):44–9.

    PubMed  Google Scholar 

  55. Nierman DM, Mechanick JI. Hypotestosteronemia in chronically critically ill men. Crit Care Med. 1999;27(11):2418–21.

    Article  CAS  PubMed  Google Scholar 

  56. Mechanick JI, Brett EM. Endocrine and metabolic issues in the management of the chronically critically ill patient. Crit Care Med. 2002;18(3):619–41.

    Google Scholar 

  57. Miller KK. Endocrine dysregulation in anorexia nervosa update. J Clin Endocrinol Metab. 2011;96(10):2939–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Isidro ML. Sexual dysfunction in men with type 2 diabetes. Postgrad Med J. 2012;88(1037):152–9.

    Article  CAS  PubMed  Google Scholar 

  59. Phé V, Rouprêt M. Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies. Diabetes Metab. 2012;38(1):1–13.

    Article  PubMed  Google Scholar 

  60. Dandona P, Dhindsa S. Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab. 2011;96(9):2643–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med. 2011;124(7):578–87.

    Article  CAS  PubMed  Google Scholar 

  62. Aftab SS, Kumar S, Barber T. The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocrinol. 2013;78(3):330–7.

    Article  Google Scholar 

  63. Du Plessis SS, Cabler S, McAlister DA, Sabanegh E, Agarwal A. The effect of obesity on sperm disorders and male infertility. Nat Rev Urol. 2010;7(3):153–61.

    Article  PubMed  Google Scholar 

  64. Hohl A, Mazzuco TL, Coral MHC, Schwarzbold M, Walz R. Hypogonadism after traumatic brain injury. Arq Bras Endocrinol Metabol. 2009;53(8):908.

    Article  PubMed  Google Scholar 

  65. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev. 2009;30(4):293–342.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Carlsen EGA, Keiding N, Skakkebaek NE. Evidence for decreasing quality of semen during past 50 years. Evidence for decreasing quality of semen during past 50 years. BMJ. 1992;305(6854):609–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Skakkebaek NE, Toppari J, Soder O, Gordon CM, Divall S, Draznin M. The exposure of fetuses and children to endocrine disrupting chemicals: a European Society for Paediatric Endocrinology (ESPE) and Pediatric Endocrine Society (PES) call to action statement. J Clin Endocrinol Metab. 2011;96(10):3056–8.

    Article  CAS  PubMed  Google Scholar 

  68. Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, et al. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ Health Perspect. 2005;113(8):1056–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Pierik FH, Burdorf A, Deddens JA, Juttmann RE, Weber RF. Maternal and paternal risk factors for cryptorchidism and hypospadias: a case-control study in newborn boys. Environ Health Perspect. 2004;112(15):1570–6.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Hardell L, Van Bavel B, Lindstrom G, Carlberg M, Dreifaldt AC, Wijkstrom H, et al. Increased concentrations of polychlorinated biphenyls, hexachlorobenzene, and chlordanes in mothers of men with testicular cancer. Environ Health Perspect. 2003;111(7):930–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Durmaz E, Ozmert EN, Erkekoglu P, Giray B, Derman O, Hincal F, et al. Plasma phthalate levels in pubertal gynecomastia. Pediatrics. 2010;125(1):e122–9.

    Article  PubMed  Google Scholar 

  72. Vieira JGH, Nakamura OH, Ferrer CM, Tachibana TT, Endo MHK, et al. Importância da Metodologia na Dosagem de Testosterona Sérica: Comparação entre um Imunoensaio Direto e um Método Fundamentado em Cromatografia. Líquida de Alta Performance e Espectrometria de Massa em Tandem (HPLC/MS-MS). Arq Bras Endocrinol Metabol. 2008;52(6):1050–5.

    Article  PubMed  Google Scholar 

  73. Appelbaum H, Malhotra S. A comprehensive approach to the spectrum of abnormal pubertal development. Adolesc Med State Art Rev. 2012;23(1):1–14.

    PubMed  Google Scholar 

  74. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–59.

    Article  CAS  PubMed  Google Scholar 

  75. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Eur J Endocrinol. 2008;159:507–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Anawalt BD, Hotaling JM, Walsh TJ, Matsumoto AM. Performance of total testosterone measurement to predict free testosterone for the biochemical evaluation of male hypogonadism. J Urol. 2012;187:1369–73.

    Article  CAS  PubMed  Google Scholar 

  77. Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med. 2011;8(3):639–54.

    Article  CAS  PubMed  Google Scholar 

  78. Giagulli VA, Triggiani V, Corona G, Carbone D, Licchelli B, et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. Curr Pharm Des. 2011;17(15):1500–11.

    Article  CAS  PubMed  Google Scholar 

  79. Meirelles RM, Hohl A. Saúde masculina: tão negligenciada, principalmente pelos homens. Arq Bras Endocrinol Metabol. 2009;53(8):899.

    Article  PubMed  Google Scholar 

  80. Corona G, Rastrelli G, Vignozzi L, Maggi M. Emerging medication for the treatment of male hypogonadism. Expert Opin Emerg Drugs. 2012;17(2):239–59.

    Article  CAS  PubMed  Google Scholar 

  81. Wang C, Swedloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men: Testosterone Gel Study. J Clin Endocrinol Metab. 2000;85:2839.

    CAS  PubMed  Google Scholar 

  82. Wang C, Ilani N, Arvert S, McLachlan RI, Soulis T, Watkinson A. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol. 2011;75:836–43.

    Article  CAS  Google Scholar 

  83. Fennell C, Sartorius G, Ly LP, Turner L, Liu PY, Conway AJ, et al. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men. Clin Endocrinol. 2010;73(1):102–9.

    CAS  Google Scholar 

  84. Hohl A, Marques MOT, Coral MHC, Walz R. Evaluation of late-onset hypogonadism (andropause) treatment using three different formulations of injectable testosterone. Arq Bras Endocrinol Metabol. 2009;53(8):989–95.

    Article  PubMed  Google Scholar 

  85. Dinsmore WW, Wyllie MG. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. BJU Int. 2012;110(2):162–9.

    Article  CAS  PubMed  Google Scholar 

  86. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 Study). Diabetes Care. 2011;34(4):828–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30:726–33.

    Article  CAS  PubMed  Google Scholar 

  88. Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, et al. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res. 2008;20:378–87.

    Article  CAS  PubMed  Google Scholar 

  89. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo controlled Moscow study. Clin Endocrinol. 2010;73:602–12.

    Article  CAS  Google Scholar 

  90. Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev. 2012;8(2):131–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Smith GD, Ben-Shlomo Y, Beswick A, et al. Cortisol, testosterone, and coronary heart disease. Prospective evidence from the Caerphilly Study. Circulation. 2005;112:332–40.

    Article  CAS  PubMed  Google Scholar 

  92. Arnlov J, Pencina MJ, Amin S, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006;145:176–84.

    Article  CAS  PubMed  Google Scholar 

  93. Vikan T, Schirmer H, Njolstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso study. Eur J Endocrinol. 2009;161:435–42.

    Article  CAS  PubMed  Google Scholar 

  94. Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009;94:2353–9.

    Article  CAS  PubMed  Google Scholar 

  95. Hyde Z, Norman PE, Flicker L, et al. Elevated luteinizing hormone predicts ischaemic heart disease events in older men. The Health In Men Study. Eur J Endocrinol. 2011;164:569–77.

    Article  CAS  PubMed  Google Scholar 

  96. Soisson V, Brailly-Tabard S, Helmer C, et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C Cohort Study. Maturitas. 2013;75:282–8.

    Article  CAS  PubMed  Google Scholar 

  97. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. J Am Coll Cardiol. 2011;58:1674–81.

    Article  CAS  PubMed  Google Scholar 

  98. Shores MM, Biggs ML, Arnold AM, et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab. 2014;99:2061–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Yeap BB, Alfonso H, Chubb SAP, et al. In older men, higher plasma testosterone or dihydrotestosterone are independent predictors for reduced incidence of stroke but not myocardial infarction. J Clin Endocrinol Metab. 2014;99:4565–73.

    Article  CAS  PubMed  Google Scholar 

  100. Srinath R, Golden SH, Carson KA, Dobs A. Endogenous testosterone and its relationship to preclinical and clinical measures of cardiovascular disease in the Atherosclerosis Risk in Communities Study. J Clin Endocrinol Metab. 2015;100:1602–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Holmegard HN, Nordestgaard BG, Jensen GB, et al. Sex hormones and ischemic stroke: a prospective cohort study and meta-analyses. J Clin Endocrinol Metab. 2016;101:69–78.

    Article  CAS  PubMed  Google Scholar 

  102. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050–8.

    Article  CAS  PubMed  Google Scholar 

  104. Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169:725–33.

    Article  CAS  PubMed  Google Scholar 

  105. Vigen R, O’Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829–36.

    Article  CAS  PubMed  Google Scholar 

  106. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9:e85805.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Baillargeon J, Urban RJ, Kuo Y-F, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48:1138–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706–15.

    Article  PubMed  Google Scholar 

  109. Anderson JL, May HT, Lappe DL, et al. Impact of testosterone replacement therapy on myocardial infarction, stroke and death in men with low testosterone concentrations in an integrated health care system. Am J Cardiol. 2016;117:794–9.

    Article  CAS  PubMed  Google Scholar 

  110. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:29–39.

    Article  CAS  PubMed  Google Scholar 

  111. Fernandez-Balsells MM, Murad MH, Lane M, et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560–75.

    Article  CAS  PubMed  Google Scholar 

  112. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Ruige JB, Ouwens DM, Kaufman J-M. Beneficial and adverse effects of testosterone on the cardiovascular system in men. J Clin Endocrinol Metab. 2013;98:4300–10.

    Article  CAS  PubMed  Google Scholar 

  114. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13:1327–51.

    Article  CAS  PubMed  Google Scholar 

  115. Borst SE, Shuster JJ, Zou B, et al. Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Med. 2014;12:21.

    Article  Google Scholar 

  116. Rhoden EL, Averbeck MA. Câncer de próstata e testosterona: riscos e controvérsias. Arq Bras Endocrinol Metabol. 2009;53(8):956–62.

    Article  PubMed  Google Scholar 

  117. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate carcinoma in hypogonadal men. J Urol. 2004;172:920; Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate carcinoma. J Urol. 2005;173:533.

    Google Scholar 

  118. Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, Lipshultz LI. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6(4):1165–70.

    Article  CAS  PubMed  Google Scholar 

  119. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate carcinoma with brachytherapy. Cancer. 2007;109:536.

    Article  CAS  PubMed  Google Scholar 

  120. Pastuszak AW, Khanna A, Badhiwala N, et al. Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer. J Urol. 2015;194(5):1271–6.

    Article  CAS  PubMed  Google Scholar 

  121. Balbontin FG, Moreno SA, Bley E, Chacon R, Silva A, Morgentaler A. Long-acting testosterone injection for treatment of testosterone deficiency after brachytherapy of prostate cancer. BJU Int. 2014;114(1):125–30.

    Article  CAS  PubMed  Google Scholar 

  122. Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate carcinoma: preliminary observations. BJU Int. 2009;103:62.

    Article  CAS  PubMed  Google Scholar 

  123. Pastuszak AW, Pearlman AM, Lai WS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190:639.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Morgentaler A. Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer. J Sex Med. 2009;6(2):574–7.

    Article  PubMed  Google Scholar 

  125. Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185(4):1256–60.

    Article  CAS  PubMed  Google Scholar 

  126. Kacker R, Hult M, San Francisco IF, Conners WP, Rojas PA, Dewolf WC, Morgentaler A. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl. 2016;18:16.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospital (Federal University of Santa Catarina), Endocrinology and Metabolism Department, Florianópolis, Santa Catarina, Brazil

    Alexandre Hohl & Marcelo Fernando Ronsoni

Authors
  1. Alexandre Hohl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcelo Fernando Ronsoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexandre Hohl .

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Agamenon Magalhães Hospital, University of Pernambuco Medical School, Recife, Pernambuco, Brazil

    Francisco Bandeira

  2. Division of Endocrinology, Mayo Clinic College of Medicine, Rochester, MN, USA

    Hossein Gharib

  3. School of Medicine, University of Pernambuco, Recife, Brazil

    Luiz Griz

  4. School of Medicine, University of Maranhao, Sao Luis, Brazil

    Manuel Faria

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hohl, A., Ronsoni, M.F. (2022). Male Hypogonadism. In: Bandeira, F., Gharib, H., Griz, L., Faria, M. (eds) Endocrinology and Diabetes. Springer, Cham. https://doi.org/10.1007/978-3-030-90684-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-90684-9_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-90683-2

  • Online ISBN: 978-3-030-90684-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation